PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24713582-2 2014 Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia. Sirolimus 28-37 low density lipoprotein receptor Homo sapiens 56-68 24713582-2 2014 Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia. Sirolimus 28-37 low density lipoprotein receptor Homo sapiens 70-75 18602894-0 2008 Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Sirolimus 0-9 low density lipoprotein receptor Homo sapiens 25-37 19180880-3 2008 The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot. Sirolimus 15-24 low density lipoprotein receptor Homo sapiens 95-127 19180880-3 2008 The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot. Sirolimus 15-24 low density lipoprotein receptor Homo sapiens 129-133 19180880-6 2008 Rapamycin dose-dependently suppressed the increased expression of LDLR induced by IL-1 beta and up-regulated the suppressed expression of ABCA1 caused by IL-1 beta. Sirolimus 0-9 low density lipoprotein receptor Homo sapiens 66-70 18602894-7 2008 However, LDL-receptor gene expression was decreased by rapamycin, suggesting that this may contribute to the hyperlipidaemia observed in rapamycin-treated patients. Sirolimus 55-64 low density lipoprotein receptor Homo sapiens 9-21 18602894-7 2008 However, LDL-receptor gene expression was decreased by rapamycin, suggesting that this may contribute to the hyperlipidaemia observed in rapamycin-treated patients. Sirolimus 137-146 low density lipoprotein receptor Homo sapiens 9-21 18602894-8 2008 Rapamycin did not affect mRNA stability, so the decrease in LDL-receptor gene expression is likely to be occurring at the transcriptional level, although independently of SREBP-2. Sirolimus 0-9 low density lipoprotein receptor Homo sapiens 60-72 17989609-5 2007 RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells. Sirolimus 9-18 low density lipoprotein receptor Homo sapiens 29-67 17989609-5 2007 RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells. Sirolimus 9-18 low density lipoprotein receptor Homo sapiens 69-73 17989609-7 2007 Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription. Sirolimus 48-57 low density lipoprotein receptor Homo sapiens 174-178 17989609-11 2007 CONCLUSIONS: This study demonstrates that the increase of LDL cholesterol by sirolimus is partly due to the reduction of LDLr on hepatocytes. Sirolimus 77-86 low density lipoprotein receptor Homo sapiens 121-125